Home

Trevena, Inc. - Common Stock (TRVN)

2.5000
0.00 (0.00%)

Trevena Inc is a biopharmaceutical company that focuses on developing innovative therapies to treat various central nervous system disorders and acute pain conditions

The company leverages its proprietary drug discovery platform to create novel molecules that target specific receptors in the brain and nervous system, aiming to provide safer and more effective treatment options. By prioritizing patient safety and reducing reliance on opioids, Trevena is actively exploring advanced therapies that can improve the quality of life for patients suffering from difficult-to-treat medical conditions.

SummaryNewsPress ReleasesChartHistoricalFAQ
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, to the board of directors of the Company, effective August 1, 2024.
By Sagimet Biosciences Inc. · Via GlobeNewswire · August 1, 2024
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027
Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons, which results in loss of memory, thinking and language skills, and behavioral changes. There is a rapid growth in the number of people living with Alzheimer’s […]
Via FinancialNewsMedia · May 9, 2023
Trevena Inc. (NASDAQ: TRVN) Near the Top of Equities by Percentage Gain on 5/8
Trevena, Inc. (NASDAQ: TRVN) is one of today’s top gainers. The company’s shares are currently up 372.94% on the day to $3.05.
Via Investor Brand Network · May 8, 2023
Trevena (NASDAQ: TRVN) Partner Receives Approval for OLINVYK in China
Trevena, Inc. (NASDAQ: TRVN) is engaged as a biopharmaceutical company, which is focused on the research, development and commercialization of
Via Spotlight Growth · May 8, 2023